MX2024001248A - Terapia de combinacion para tratar el crecimiento celular anormal. - Google Patents

Terapia de combinacion para tratar el crecimiento celular anormal.

Info

Publication number
MX2024001248A
MX2024001248A MX2024001248A MX2024001248A MX2024001248A MX 2024001248 A MX2024001248 A MX 2024001248A MX 2024001248 A MX2024001248 A MX 2024001248A MX 2024001248 A MX2024001248 A MX 2024001248A MX 2024001248 A MX2024001248 A MX 2024001248A
Authority
MX
Mexico
Prior art keywords
cell growth
abnormal cell
treating abnormal
combination therapy
inhibitor
Prior art date
Application number
MX2024001248A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan A Pachter
Silvia Coma
Brian M Stuglik
Julian Downward
Arcas Miriam Molina
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of MX2024001248A publication Critical patent/MX2024001248A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024001248A 2021-07-27 2022-07-27 Terapia de combinacion para tratar el crecimiento celular anormal. MX2024001248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163203555P 2021-07-27 2021-07-27
PCT/US2022/038434 WO2023009572A1 (en) 2021-07-27 2022-07-27 Combination therapy for treating abnormal cell growth

Publications (1)

Publication Number Publication Date
MX2024001248A true MX2024001248A (es) 2024-04-18

Family

ID=85087234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001248A MX2024001248A (es) 2021-07-27 2022-07-27 Terapia de combinacion para tratar el crecimiento celular anormal.

Country Status (10)

Country Link
US (1) US20250049792A1 (enExample)
EP (1) EP4376828A4 (enExample)
JP (1) JP2024528039A (enExample)
KR (1) KR20240041978A (enExample)
CN (1) CN118103040A (enExample)
AU (1) AU2022318885A1 (enExample)
CA (1) CA3227498A1 (enExample)
IL (1) IL310477A (enExample)
MX (1) MX2024001248A (enExample)
WO (1) WO2023009572A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
EP4595963A4 (en) * 2022-09-30 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE
WO2024173761A1 (en) * 2023-02-17 2024-08-22 Ikena Oncology, Inc. Combinations comprising mek inhibitors for use in the treatment of cancer
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) * 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115376A1 (en) * 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
CN115151533B (zh) * 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途

Also Published As

Publication number Publication date
EP4376828A1 (en) 2024-06-05
KR20240041978A (ko) 2024-04-01
US20250049792A1 (en) 2025-02-13
WO2023009572A1 (en) 2023-02-02
JP2024528039A (ja) 2024-07-26
CA3227498A1 (en) 2023-02-02
CN118103040A (zh) 2024-05-28
EP4376828A4 (en) 2025-06-18
IL310477A (en) 2024-03-01
AU2022318885A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
MX2024005024A (es) Terapia combinada para tratar crecimiento celular anormal.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2021002804A (es) Terapias de combinacion.
MX2024008551A (es) Terapias de combinacion.
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2020014009A2 (es) Inhibidores de mcl-1
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
MX389204B (es) Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cáncer hematológico.
BR112023015616A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
ES3063700T3 (en) Mirikizumab in the treatment of ulcerative colitis
MX2021013815A (es) Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CO2024009571A2 (es) Inhibidores de parp1
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
CO2020014599A2 (es) Métodos para tratar cáncer
MX2019014330A (es) Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax.
BR112022010278A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila
CL2025000366A1 (es) Composiciones y metodos para el tratamiento de presicion del cancer
CL2018002136A1 (es) Combinaciones de dihidrocloruro de histamina y uso de estas